Photocure (DB:PHS) - Stock Price, News & Analysis

PHS Stock Overview

Engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. More details

PHS fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 87.2% below our estimate of its fair value

Earnings are forecast to grow 94.94% per year

Became profitable this year

Risk Analysis

Shares are highly illiquid

Photocure ASA Competitors

Pierrel

DB:2FJ0

€92.8m

PharmaSGP Holding

XTRA:PSG

€287.8m

MPH Health Care

DB:93M1

€105.3m

Dermapharm Holding

XTRA:DMP

€2.0b

Price History & Performance

Summary of all time highs, changes and price drops for Photocure
Historical stock prices
Current Share Price	NOK 4.41
52 Week High	NOK 4.84
52 Week Low	NOK 4.28
Beta	0.99
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-62.72%
5 Year Change	n/a
Change since IPO	-25.88%

Recent updates

Shareholder Returns

	PHS	DE Pharmaceuticals	DE Market
7D	0%	1.4%	0.8%
1Y	n/a	-18.4%	9.1%

Return vs Industry: Insufficient data to determine how PHS performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how PHS performed against the German Market.

Price Volatility

Is PHS's price volatile compared to industry and market?
PHS volatility
PHS Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: PHS's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine PHS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1993	102	Dan Schneider	www.photocure.com

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer.

Photocure ASA Fundamentals Summary

How do Photocure's earnings and revenue compare to its market cap?
PHS fundamental statistics
Market cap	€117.53m
Earnings (TTM)	€1.22m
Revenue (TTM)	€45.18m

96.6x

P/E Ratio

2.6x

P/S Ratio

Is PHS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHS income statement (TTM)
Revenue	NOK 526.25m
Cost of Revenue	NOK 29.11m
Gross Profit	NOK 497.15m
Other Expenses	NOK 482.98m
Earnings	NOK 14.16m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.52
Gross Margin	94.47%
Net Profit Margin	2.69%
Debt/Equity Ratio	0%

How did PHS perform over the long term?

See historical performance and comparison

PHS Stock Overview

Rewards

Risk Analysis

Photocure ASA Competitors

DB:2FJ0

€92.8m

XTRA:PSG

€287.8m

DB:93M1

€105.3m

XTRA:DMP

€2.0b

Price History & Performance

Recent News & Updates

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

Photocure ASA Announces Board Appointments

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Less than half of directors are independent

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Recent updates

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

Photocure ASA Announces Board Appointments

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Less than half of directors are independent

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China

Photocure ASA Announces Change of Board Composition

Less than half of directors are independent

Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint

Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.81 loss in 1Q 2022)

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy

Third quarter 2022 earnings released: kr0.37 loss per share (vs kr0.27 loss in 3Q 2021)

Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc

PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S

Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology

Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Second quarter 2022 earnings released: kr0.68 loss per share (vs kr0.40 loss in 2Q 2021)

Second quarter 2022 earnings released: kr0.68 loss per share (vs kr0.40 loss in 2Q 2021)

Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States

Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022.

Full year 2021 earnings released: kr1.15 loss per share (vs kr0.91 loss in FY 2020)

Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S

Third quarter 2021 earnings released: kr0.27 loss per share (vs kr0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology

Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020.

Photocure ASA Suspends Guidance for 2023

New 90-day high: €10.40

Photocure ASA to Report Q3, 2021 Results on Nov 17, 2021

Asieris Pharmaceuticals and Photocure ASA Expands Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan

Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan

New 90-day high: €9.02

Photocure Announces New Cevira Patent In Europe

Photocure Launches European Hexvix Operations

Photocure ASA Provides Revenue Guidance for the Year 2020

Shareholder Returns

Price Volatility

About the Company

Photocure ASA Fundamentals Summary

96.6x

2.6x

Earnings & Revenue